Immunocore, Ltd. achieved several firsts with the US Food and Drug Administration approval of Kimmtrak (tebentafusp-tebn) – it is the first approved T-cell receptor (TCR) therapy, the first drug approved for metastatic uveal melanoma and Immunocore’s first approved product. But executives said in a same-day conference call that Immunocore is ready for its first-ever commercial launch.
The bispecific immunotherapy was approved on 26 January, a month before the FDA user fee date, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Also see "J.P
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?